{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T10:33:02Z","timestamp":1784370782359,"version":"3.55.0"},"reference-count":101,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2020,6,16]],"date-time":"2020-06-16T00:00:00Z","timestamp":1592265600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,6,16]],"date-time":"2020-06-16T00:00:00Z","timestamp":1592265600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nephrol"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1007\/s40620-020-00776-3","type":"journal-article","created":{"date-parts":[[2020,6,16]],"date-time":"2020-06-16T15:02:46Z","timestamp":1592319766000},"page":"1081-1090","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Renal disorders in rheumatologic diseases: the spectrum is changing (part 2. Arthridides)"],"prefix":"10.1093","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6060-965X","authenticated-orcid":false,"given":"Claudio","family":"Ponticelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Doria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"Moroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,6,16]]},"reference":[{"key":"776_CR1","doi-asserted-by":"publisher","first-page":"797","DOI":"10.7326\/0003-4819-146-11-200706050-00008","volume":"146","author":"K Nishimura","year":"2007","unstructured":"Nishimura K, Sugiyama D, Kogata Y, Tsuji G, Nakazawa T, Kawano S et al (2007) Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. Ann Intern Med 146:797\u2013808","journal-title":"Ann Intern Med"},{"key":"776_CR2","doi-asserted-by":"publisher","first-page":"R16","DOI":"10.1186\/ar4148","volume":"15","author":"N Bizzaro","year":"2013","unstructured":"Bizzaro N, Bartoloni E, Morozzi G, Manganelli S, Riccieri V, Sabatini P et al (2013) Anti-cyclic citrullinated peptide antibody titer predicts time to rheumatoid arthritis onset in patients with undifferentiated arthritis: results from a 2-year prospective study. Arthritis Res Ther 15:R16","journal-title":"Arthritis Res Ther"},{"key":"776_CR3","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/nri.2016.124","volume":"17","author":"V Malmstrom","year":"2017","unstructured":"Malmstrom V, Catrina AI, Klareskog L (2017) The immunopathogenesis of seropositive rheumatoid arthritis: from triggering to targeting. Nat Rev Immunol 17:60\u201375","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"776_CR4","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1111\/imr.12829","volume":"294","author":"M Volkov","year":"2020","unstructured":"Volkov M, van Schie KA, van der Woude D (2020) Autoantibodies and B Cells: The ABC of rheumatoid arthritis pathophysiology. Immunol Rev 294(1):148\u2013163","journal-title":"Immunol Rev"},{"issue":"3","key":"776_CR5","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1159\/000183671","volume":"42","author":"H Helin","year":"1986","unstructured":"Helin H, Korpela M, Mustonen J, Pasternack A (1986) Mild mesangial glomerulopathy\u2013a frequent finding in rheumatoid arthritis patients with hematuria or proteinuria. Nephron 42(3):224\u2013230","journal-title":"Nephron"},{"issue":"6","key":"776_CR6","first-page":"1000","volume":"16","author":"A Yoshida","year":"1994","unstructured":"Yoshida A, Morozumi K, Takeda A, Koyama K, Oikawa T (1994) Membranous glomerulonephritis in patients with rheumatoid arthritis. Clin Ther 16(6):1000\u20131006","journal-title":"Clin Ther"},{"issue":"2","key":"776_CR7","first-page":"87","volume":"27","author":"E Honkanen","year":"1987","unstructured":"Honkanen E, T\u00f6rnroth T, Pettersson E, Skrifvars B (1987) Membranous glomerulonephritis in rheumatoid arthritis not related to gold or d-penicillamine therapy: a report of four cases and review of the literature. Clin Nephrol 27(2):87\u201393","journal-title":"Clin Nephrol"},{"issue":"11","key":"776_CR8","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1093\/rheumatology\/32.11.1008","volume":"32","author":"D Adu","year":"1993","unstructured":"Adu D, Berisa F, Howie AJ, Emery P, Bacon PA, McConkey B et al (1993) Glomerulonephritis in rheumatoid arthritis. Br J Rheumatol 32(11):1008\u20131011","journal-title":"Br J Rheumatol"},{"issue":"4","key":"776_CR9","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1159\/000168636","volume":"13","author":"J Almirall","year":"1993","unstructured":"Almirall J, Alcorta I, Botey A, Revert L (1993) Penicillamine-induced rapidly progressive glomerulonephritis in a patient with rheumatoid arthritis. Am J Nephrol 13(4):286\u2013288","journal-title":"Am J Nephrol"},{"issue":"11","key":"776_CR10","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1111\/1756-185X.12612","volume":"20","author":"AM Alkhunaizi","year":"2017","unstructured":"Alkhunaizi AM, Dawamneh MF (2017) ANCA-positive crescentic glomerulonephritis in a patient with rheumatoid arthritis treated with anti-tumor necrosis factor alpha. Int J Rheum Dis 20(11):1843\u20131847","journal-title":"Int J Rheum Dis"},{"issue":"7","key":"776_CR11","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1093\/ndt\/gfh832","volume":"20","author":"MB Stokes","year":"2005","unstructured":"Stokes MB, Foster K, Markowitz GS, Ebrahimi F, Hines W, Kaufman D et al (2005) Development of glomerulonephritis during anti-TNF-alpha therapy for rheumatoid arthritis. Nephrol Dial Transplant 20(7):1400\u20131406","journal-title":"Nephrol Dial Transplant"},{"key":"776_CR12","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/j.mayocp.2012.04.011","volume":"87","author":"O Sokumbi","year":"2012","unstructured":"Sokumbi O, Wetter DA, Makol A, Warrington KJ (2012) Vasculitis associated with tumor necrosis factor-\u03b1 inhibitors. Mayo Clin Proc 87:739\u2013745","journal-title":"Mayo Clin Proc"},{"issue":"6","key":"776_CR13","first-page":"1122","volume":"34","author":"Y Asami","year":"2016","unstructured":"Asami Y, Ishiguro H, Ueda A, Nakajima H (2016) First report of membranous nephropathy and systemic lupus erythematosus associated with abatacept in rheumatoid arthritis. Clin Exp Rheumatol 34(6):1122","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"776_CR14","doi-asserted-by":"publisher","first-page":"44","DOI":"10.4103\/1319-2442.198118","volume":"28","author":"P Muthukumar","year":"2017","unstructured":"Muthukumar P, Dhanapriya J, Gopalakrishnan N, Dineshkumar T, Sakthirajan R, Balasubramaniyan T (2017) Evaluation of renal lesions and clinicopathologic correlation in rheumatoid arthritis. Saudi J Kidney Dis Transpl 28(1):44\u201350","journal-title":"Saudi J Kidney Dis Transpl"},{"key":"776_CR15","doi-asserted-by":"publisher","DOI":"10.1007\/s10238-019-00602-6","author":"T Zhang","year":"2020","unstructured":"Zhang T, Liang S, Feng X, Li M, Zhou H, Zeng C, Zhang J, Cheng Z (2020) Spectrum and prognosis of renal histopathological lesions in 56 Chinese patients with rheumatoid arthritis with renal involvement. Clin Exp Med. https:\/\/doi.org\/10.1007\/s10238-019-00602-6(Epub ahead of print)","journal-title":"Clin Exp Med"},{"issue":"bcr07","key":"776_CR16","doi-asserted-by":"publisher","first-page":"0394","DOI":"10.1136\/bcr.07.2008.0394","volume":"2009","author":"L Marinchev","year":"2008","unstructured":"Marinchev L, Atanasova S, Robeva R, Todorov T (2009) Diffuse mesangial IgA glomerulonephritis in a patient with rheumatoid arthritis: a possible extra-articular manifestation in rheumatoid arthritis. BMJ Case Rep 2009:bcr07.2008.0394. https:\/\/doi.org\/10.1136\/bcr.07.2008.0394","journal-title":"BMJ Case Rep"},{"key":"776_CR17","doi-asserted-by":"publisher","first-page":"2372","DOI":"10.1002\/art.39771","volume":"68","author":"JD Kinslow","year":"2016","unstructured":"Kinslow JD, Blum LK, Deane KD et al (2016) Elevated IgA plasmablast levels in subjects at risk of developing rheumatoid arthritis. Arthritis Rheumatol 68:2372\u20132383","journal-title":"Arthritis Rheumatol"},{"key":"776_CR18","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1038\/ki.2010.89","volume":"77","author":"M Praga","year":"2010","unstructured":"Praga M, Gonz\u00e1lez E (2010) Acute interstitial nephritis. Kidney Int 77:956","journal-title":"Kidney Int"},{"issue":"9","key":"776_CR19","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.2215\/CJN.08090719","volume":"14","author":"E M\u00e9rida","year":"2019","unstructured":"M\u00e9rida E, Praga M (2019) NSAIDs and nephrotic syndrome. Clin J Am Soc Nephrol 14(9):1280\u20131282","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"776_CR20","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1053\/j.ackd.2016.11.016","volume":"24","author":"CC Nast","year":"2017","unstructured":"Nast CC (2017) Medication-induced interstitial nephritis in the 21st century. Adv Chronic Kidney Dis 24(2):72\u201379","journal-title":"Adv Chronic Kidney Dis"},{"key":"776_CR21","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1038\/sj.ki.5002776","volume":"73","author":"E Gonz\u00e1lez","year":"2008","unstructured":"Gonz\u00e1lez E, Guti\u00e9rrez E, Galeano C, Chevia C, de Sequera P, Bernis C et al (2008) Early steroid treatment improves the recovery of renal function in patients with drug-induced acute interstitial nephritis. Kidney Int 73:940\u2013946","journal-title":"Kidney Int"},{"key":"776_CR22","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1097\/00075198-200112000-00003","volume":"7","author":"AJ Olyaei","year":"2001","unstructured":"Olyaei AJ, De Mattos AM, Bennett WM (2001) Nephrotoxicity of immunosuppressive drugs: new insight and preventive strategies. Curr Opin Crit Care 7:384\u2013389","journal-title":"Curr Opin Crit Care"},{"issue":"1","key":"776_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00795-016-0146-3","volume":"50","author":"T Tanaka","year":"2017","unstructured":"Tanaka T (2017) A mechanistic link between renal ischemia and fibrosis. Med Mol Morphol 50(1):1\u20138","journal-title":"Med Mol Morphol"},{"key":"776_CR24","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1111\/j.1523-1755.2005.00327.x","volume":"67","author":"S Matsuo","year":"2005","unstructured":"Matsuo S, Lopez-Guisa JM, Cai X, Okamura DM, Alpers CE, Bumgarner RE, Peters MA et al (2005) Multifunctionality of PAI-1 in fibrogenesis: evidence from obstructive nephropathy in PAI-1-overexpressing mice. Kidney Int 67:2221\u20132238","journal-title":"Kidney Int"},{"key":"776_CR25","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1038\/sj.ki.5001846","volume":"70","author":"G Wolf","year":"2006","unstructured":"Wolf G (2006) Renal injury due to renin-angiotensin-aldosterone system activation of the transforming growth factor-beta pathway. Kidney Int 70:1914\u20131919","journal-title":"Kidney Int"},{"issue":"10","key":"776_CR26","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1002\/art.24735","volume":"61","author":"L Obici","year":"2009","unstructured":"Obici L, Raimondi S, Lavaelli F, Bellotti V, Merlini G (2009) Susceptibility to AA amyloidosis in rheumaticdiseases: a critical overview. Arthritis Rheum 61(10):1435\u20131440","journal-title":"Arthritis Rheum"},{"issue":"4","key":"776_CR27","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/j.rdc.2018.06.004","volume":"44","author":"R Papa","year":"2018","unstructured":"Papa R, Lachmann HJ (2018) Secondary, AA amyloidosis. Rheum Dis Clin North Am 44(4):585\u2013603","journal-title":"Rheum Dis Clin North Am"},{"key":"776_CR28","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1093\/rheumatology\/keg101","volume":"42","author":"S Mpofu","year":"2003","unstructured":"Mpofu S, Teh LS, Smith PJ, Moots RJ, Hawkins PN (2003) Cytostatic therapy for AA amyloidosis complicating psoriatic spondyloarthropathy. Rheumatol (Oxford) 42:362\u2013366","journal-title":"Rheumatol (Oxford)"},{"key":"776_CR29","doi-asserted-by":"publisher","first-page":"2571","DOI":"10.1002\/art.10581","volume":"46","author":"O Elkayam","year":"2002","unstructured":"Elkayam O, Hawkins PN, Lachmann H, Yaron M, Caspi D (2002) Rapid and complete resolution of proteinuria due to renal amyloidosis in a patient with rheumatoid arthritis treated with infliximab. Arthritis Rheum 46:2571\u20132573","journal-title":"Arthritis Rheum"},{"key":"776_CR30","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1093\/rheumatology\/keh128","volume":"43","author":"J Ravindran","year":"2004","unstructured":"Ravindran J, Shenker N, Bhalla AK, Lachmann H, Hawkins P (2004) Case report: response in proteinuria due to AA amyloidosis but not Felty\u2019s syndrome in a patient with rheumatoid arthritis treated with TNF-alpha blockade. Rheumatol (Oxford) 43:669\u2013672","journal-title":"Rheumatol (Oxford)"},{"issue":"4","key":"776_CR31","doi-asserted-by":"publisher","first-page":"E136","DOI":"10.3390\/biom8040136","volume":"8","author":"L Kilic","year":"2018","unstructured":"Kilic L, Erden A, Sener YZ, Armagan B, Sari A, Kalyoncu U et al (2018) Rituximab therapy in renal amyloidosis secondary to rheumatoid arthritis. Biomolecules 8(4):E136","journal-title":"Biomolecules"},{"key":"776_CR32","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1093\/med\/9780198784081.003.0003","volume-title":"Treatment of primary glomerulonephritis","author":"C Ponticelli","year":"2019","unstructured":"Ponticelli C, Glassock RJ (2019) The pharmacology of old and new agents for specific therapy of primary glomerular diseases. In: Ponticelli C, Glassock RJ (eds) Treatment of primary glomerulonephritis, 3rd edn. Oxford University Press, Oxford, pp 71\u2013174","edition":"3"},{"issue":"12","key":"776_CR33","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.2215\/CJN.00150118","volume":"13","author":"MA Perazella","year":"2018","unstructured":"Perazella MA (2018) Pharmacology behind common drug nephrotoxicity. Lin J Am Soc Nephrol 13(12):1897\u20131908","journal-title":"Lin J Am Soc Nephrol"},{"issue":"3","key":"776_CR34","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1053\/sarh.2000.16641","volume":"30","author":"MH Schiff","year":"2000","unstructured":"Schiff MH, Whelton A (2000) Renal toxicity associated with disease-modifying antirheumatic drugs used for the treatment of rheumatoid arthritis. Semin Arthritis Rheum 30(3):196\u2013208","journal-title":"Semin Arthritis Rheum"},{"issue":"7","key":"776_CR35","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.2215\/CJN.02050309","volume":"4","author":"MA Perazella","year":"2009","unstructured":"Perazella MA (2009) Renal vulnerability to drug toxicity. Clin J Am Soc Nephrol 4(7):1275\u20131283","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"776_CR36","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/s41584-020-0370-z","volume":"16","author":"F Buttgereit","year":"2020","unstructured":"Buttgereit F (2020) Views on glucocorticoid therapy in rheumatology: the age of convergence. Nat Rev Rheumatol 16(4):239\u2013246","journal-title":"Nat Rev Rheumatol"},{"issue":"12","key":"776_CR37","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1038\/nrrheum.2010.179","volume":"6","author":"JN Hoes","year":"2010","unstructured":"Hoes JN, Jacobs JW, Buttgereit F, Bijlsma JW (2010) Current view of glucocorticoid co-therapy with DMARDs in rheumatoid arthritis. Nat Rev Rheumatol 6(12):693\u2013702","journal-title":"Nat Rev Rheumatol"},{"issue":"353","key":"776_CR38","doi-asserted-by":"publisher","first-page":"i1777","DOI":"10.1136\/bmj.i1777","volume":"21","author":"GS Hazlewood","year":"2016","unstructured":"Hazlewood GS, Barnabe C, Tomlinson G, Marshall D, Devoe D, Bombardier C (2016) Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying antirheumatic drugs for rheumatoid arthritis: abridged cochrane systematic review and network meta-analysis. BMJ 21(353):i1777. https:\/\/doi.org\/10.1136\/bmj.i1777","journal-title":"BMJ"},{"issue":"11","key":"776_CR39","doi-asserted-by":"publisher","first-page":"2977","DOI":"10.1007\/s10067-019-04699-8","volume":"38","author":"S Tavakolpour","year":"2019","unstructured":"Tavakolpour S, Alesaeidi S, Darvishi M, GhasemiAdl M, Darabi-Monadi S, Akhlaghdoust M, Elikaei Behjati S, Jafarieh A (2019) A comprehensive review of rituximab therapy in rheumatoid arthritis patients. Clin Rheumatol 38(11):2977\u20132994","journal-title":"Clin Rheumatol"},{"key":"776_CR40","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-216655","author":"JS Smolen","year":"2020","unstructured":"Smolen JS, Landew\u00e9 RBM, Bijlsma JWJ, Burmester GR, Dougados M, Kerschbaumer A et al (2020) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. https:\/\/doi.org\/10.1136\/annrheumdis-2019-216655(pii: annrheumdis-2019-216655. Epub ahead of print)","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"776_CR41","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1056\/NEJMra0804595","volume":"361","author":"FO Nestle","year":"2009","unstructured":"Nestle FO, Kaplan DH, Barker J (2009) Psoriasis. N Engl J Med 361(5):496\u2013509","journal-title":"N Engl J Med"},{"issue":"10","key":"776_CR42","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1056\/NEJMra1505557","volume":"376","author":"CT Ritchlin","year":"2017","unstructured":"Ritchlin CT, Colbert RA, Gladman DD (2017) Psoriasic Arthritis. N Engl J Med 376(10):957\u2013970","journal-title":"N Engl J Med"},{"issue":"8","key":"776_CR43","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1002\/art.23104","volume":"57","author":"V Chandran","year":"2007","unstructured":"Chandran V, Schentag CT, Gladman DD (2007) Sensitivity of the classification of psoriatic arthritis criteria in early psoriatic arthritis. Arthritis Rheum 57(8):1560\u20131563","journal-title":"Arthritis Rheum"},{"issue":"10","key":"776_CR44","first-page":"2069","volume":"35","author":"V Chandran","year":"2008","unstructured":"Chandran V, Schentag CT, Gladman DD (2008) Sensitivity and specificity of the CASPAR criteria for psoriatic arthritis in a family medicine clinic setting. J Rheumatol 35(10):2069\u20132070","journal-title":"J Rheumatol"},{"issue":"Suppl 1","key":"776_CR45","doi-asserted-by":"publisher","first-page":"S88","DOI":"10.1016\/j.clim.2008.03.247","volume":"127","author":"R Winchester","year":"2008","unstructured":"Winchester R, Minevich G, Kane D, Bresnihan B, Greenberg D, FitzGerald O (2008) Heterogeneity of the psoriasis phenotype revealed by HLA class I haplotype associations in psoriatic arthritis and psoriasis. Clin Immunol 127(Suppl 1):S88\u2013S89","journal-title":"Clin Immunol"},{"key":"776_CR46","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1136\/ard.2007.071399","volume":"67","author":"PY Ho","year":"2008","unstructured":"Ho PY, Barton A, Worthington J, Plant D, Griffiths CE, Young HS et al (2008) Investigating the role of the HLA-Cw*06 and HLA-DRB1 genes in susceptibility to psoriatic arthritis: comparison with psoriasis and undifferentiated inflammatory arthritis. Ann Rheum Dis 67:677\u2013682","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"776_CR47","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1186\/ar2580","volume":"11","author":"O FitzGerald","year":"2009","unstructured":"FitzGerald O, Winchester R (2009) Psoriatic arthritis: from pathogenesis to treatment. Arthritis Res Ther 11(1):214","journal-title":"Arthritis Res Ther"},{"key":"776_CR48","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.1016\/S0140-6736(18)30830-4","volume":"391","author":"DJ Veale","year":"2018","unstructured":"Veale DJ, Fearon U (2018) The pathogenesis of psoriatic arthritis. Lancet 391:2273\u20132284","journal-title":"Lancet"},{"key":"776_CR49","doi-asserted-by":"publisher","first-page":"F1000 Faculty R","DOI":"10.12688\/f1000research.19144.1","volume":"8","author":"V Ocampo","year":"2019","unstructured":"Ocampo V, Gladman D (2019) Psoriatic arthritis. F1000 Res. 8:F1000 Faculty Rev-1665. https:\/\/doi.org\/10.12688\/f1000research.19144.1","journal-title":"F1000 Res"},{"issue":"Supplement_1","key":"776_CR50","doi-asserted-by":"publisher","first-page":"i4","DOI":"10.1093\/rheumatology\/kez325","volume":"9","author":"R Winchester","year":"2020","unstructured":"Winchester R, FitzGerald O (2020) 2020 The many faces of psoriatic arthritis: their genetic determinism. Rheumatology (Oxford) 9(Supplement_1):i4\u2013i9","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"776_CR51","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.rdc.2015.07.008","volume":"41","author":"ME Husni","year":"2015","unstructured":"Husni ME (2015) Comorbidities in psoriatic arthritis. Rheum Dis Clin North Am 41(4):677\u2013698","journal-title":"Rheum Dis Clin North Am"},{"key":"776_CR52","doi-asserted-by":"publisher","first-page":"108397","DOI":"10.1016\/j.clim.2020.108397","volume":"214","author":"LM Perez-Chada","year":"2020","unstructured":"Perez-Chada LM, Merola JF (2020) Comorbidities associated with psoriatic arthritis: review and update. Clin Immunol 214:108397","journal-title":"Clin Immunol"},{"issue":"2","key":"776_CR53","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1001\/jamadermatol.2014.2094","volume":"151","author":"J Takeshita","year":"2015","unstructured":"Takeshita J, Wang S, Shin DB, Mehta NN, Kimmel SE, Margolis DJ et al (2015) Effect of psoriasis severity on hypertension control: a population-based study in the United Kingdom. JAMA Dermatol 151(2):161\u2013169","journal-title":"JAMA Dermatol"},{"issue":"3","key":"776_CR54","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.jdermsci.2015.03.012","volume":"78","author":"CC Chi","year":"2015","unstructured":"Chi CC, Wang J, Chen YF, Wang SH, Chen FL, Tung TH (2015) Risk of incident chronic kidney disease and end-stage renal disease in patients with psoriasis: a nationwide population-based cohort study. J Dermatol Sci 78(3):232\u2013238","journal-title":"J Dermatol Sci"},{"issue":"2","key":"776_CR55","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1111\/bjd.14302","volume":"174","author":"ZK Jabbar-Lopez","year":"2016","unstructured":"Jabbar-Lopez ZK, Weatherhead SC, Reynolds NJ (2016) Kidney disease in moderate-to-severe psoriasis: a critical appraisal. Br J Dermatol 174(2):267\u2013270","journal-title":"Br J Dermatol"},{"issue":"7","key":"776_CR56","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1007\/s11255-018-1868-z","volume":"50","author":"P Ungprasert","year":"2018","unstructured":"Ungprasert P, Raksasuk S (2018) Psoriasis and risk of incident chronic kidney disease and end-stage renal disease: a systematic review and meta-analysis. Int Urol Nephrol 50(7):1277\u20131283","journal-title":"Int Urol Nephrol"},{"issue":"9","key":"776_CR57","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1111\/1346-8138.14531","volume":"45","author":"CC Wang","year":"2018","unstructured":"Wang CC, Tang CH, Huang KC, Huang SY, Sue YM (2018) Increased risk of incident psoriasis in end-stage renal disease patients on chronic hemodialysis: a nationwide population-based cohort study. J Dermatol 45(9):1063\u20131070","journal-title":"J Dermatol"},{"issue":"1","key":"776_CR58","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1111\/bjd.13599","volume":"173","author":"HY Chiu","year":"2015","unstructured":"Chiu HY, Huang HL, Li CH, Yin YJ, Chen HA, Hsu ST et al (2015) Increased risk of glomerulonephritis and chronic kidney disease in relation to the severity of psoriasis, concomitant medication, and comorbidity: a nationwide population-based cohort study. Br J Dermatol 173(1):146\u2013154","journal-title":"Br J Dermatol"},{"issue":"5","key":"776_CR59","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1080\/030097401753180345","volume":"30","author":"GM Alenius","year":"2001","unstructured":"Alenius GM, Stegmayr BG, Dahlqvist SR (2001) Renal abnormalities in a population of patients with psoriatic arthritis. Scand J Rheumatol 30(5):271\u2013274","journal-title":"Scand J Rheumatol"},{"issue":"6","key":"776_CR60","first-page":"1107","volume":"23","author":"Q Ahmed","year":"1996","unstructured":"Ahmed Q, Chung-Park M, Mustafa K, Khan MA (1996) Psoriatic spondyloarthropathy with secondary amyloidosis. J Rheumatol 23(6):1107\u20131110","journal-title":"J Rheumatol"},{"issue":"5","key":"776_CR61","first-page":"250","volume":"39","author":"L Grcevska","year":"1993","unstructured":"Grcevska L, Polenakovi\u0107 M, Ferluga D, Vizjak A, Stavri\u0107 G (1993) Membranous nephropathy with severe tubulointerstitial and vascular changes in a patient with psoriatic arthritis treated with non-steroidal anti-inflammatory drugs. Clin Nephrol 39(5):250\u2013253","journal-title":"Clin Nephrol"},{"issue":"9","key":"776_CR62","first-page":"522","volume":"43","author":"Y Hiki","year":"1993","unstructured":"Hiki Y, Kokubo T, Horii A, Yokouchi S, Satoh M, Kuwao S et al (1993) A case of severe IgA nephropathy associated with psoriatic arthritis and idiopathic interstitial pneumonia. Acta Pathol Jpn 43(9):522\u2013528","journal-title":"Acta Pathol Jpn"},{"issue":"8","key":"776_CR63","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1093\/ndt\/13.8.2104","volume":"13","author":"MI Quarenghi","year":"1998","unstructured":"Quarenghi MI, Del Vecchio L, Casartelli D, Manunta P, Rossi R (1998) MPO antibody-positive vasculitis in a patient with psoriatic arthritis and gold-induced membranous glomerulonephritis. Nephrol Dial Transplant 13(8):2104\u20132216","journal-title":"Nephrol Dial Transplant"},{"issue":"68","key":"776_CR64","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/art.39573","volume":"2016","author":"LC Coates","year":"2016","unstructured":"Coates LC, Kavanaugh A, SorianoLaura MPJER, Acosta-Felquer M, Armstrong AW et al (2016) Group for research and assessment of psoriasis and psoriatic arthritis 2015 treatment recommendations for psoriatic arthritis. Arthritis Rheumatol 2016(68):1060\u20131071","journal-title":"Arthritis Rheumatol"},{"key":"776_CR65","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1136\/annrheumdis-2015-208337","volume":"75","author":"L Gossec","year":"2016","unstructured":"Gossec L, Smolen JS, Ramiro S, de Wit M, Cutolo M, Dougados M et al (2016) European league against rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Ann Rheum Dis 75:499\u2013510","journal-title":"Ann Rheum Dis"},{"key":"776_CR66","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1002\/art.40726","volume":"71","author":"JA Singh","year":"2019","unstructured":"Singh JA, Guyatt G, OgdieGladman ADD, Deal C, Deodhar A et al (2019) Special article: 2018 American college of rheumatology\/national psoriasis foundation guideline for the treatment of psoriatic arthritis. Arthritis Rheumatol 71:5\u201332","journal-title":"Arthritis Rheumatol"},{"issue":"Suppl 1","key":"776_CR67","doi-asserted-by":"publisher","first-page":"i37","DOI":"10.1093\/rheumatology\/kez383","volume":"59","author":"A Ogdie","year":"2020","unstructured":"Ogdie A, Coates L, Gladman D (2020) Treatment guidelines in psoriatic arthritis. Rheumatology (Oxford) 59(Suppl 1):i37\u2013i46","journal-title":"Rheumatology (Oxford)"},{"issue":"10","key":"776_CR68","doi-asserted-by":"publisher","first-page":"e197","DOI":"10.1371\/journal.pmed.0050197","volume":"5","author":"MJ Caulfield","year":"2008","unstructured":"Caulfield MJ, Munroe PB, O'Neill D, Witkowska K, Charchar FJ, Doblado M et al (2008) SLC2A9 is a high-capacity urate transporter in humans. PLoS Med 5(10):e197","journal-title":"PLoS Med"},{"issue":"1","key":"776_CR69","doi-asserted-by":"publisher","first-page":"4939","DOI":"10.1038\/s41598-017-04949-2","volume":"7","author":"W Wu","year":"2017","unstructured":"Wu W, Bush KT, Nigam SK (2017) Key role for the organic anion transporters, OAT1 and OAT3, in the in vivo handling of uremic toxins and solutes. Sci Rep 7(1):4939","journal-title":"Sci Rep"},{"issue":"4","key":"776_CR70","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1097\/MNH.0000000000000427","volume":"27","author":"SK Nigam","year":"2018","unstructured":"Nigam SK, Bhatnagar V (2018) The systems biology of uric acid transporters: the role of remote sensing and signaling. Curr Opin Nephrol Hypertens 27(4):305\u2013313","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"6","key":"776_CR71","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1053\/j.ackd.2012.07.009","volume":"19","author":"IA Bobulescu","year":"2012","unstructured":"Bobulescu IA, Moe OW (2012) Renal transport of uric acid: evolving concepts and uncertainties. Adv Chronic Kidney Dis 19(6):358\u2013371","journal-title":"Adv Chronic Kidney Dis"},{"issue":"4\u20136","key":"776_CR72","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1080\/15257770.2013.854902","volume":"33","author":"T Takada","year":"2014","unstructured":"Takada T, Ichida K, Matsuo H, Nakayama A, Murakami K, Yamanashi Y et al (2014) ABCG2 dysfunction increases serum uric acid by decreased intestinal urate excretion. Nucleosides Nucleotides Nucleic Acids 33(4\u20136):275\u2013281","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"776_CR73","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1007\/s11926-016-0587-7","volume":"18","author":"D Hyndman","year":"2016","unstructured":"Hyndman D, Liu S, Miner JN (2016) Urate handling in the human body. Curr Rheumatol Rep 18:34","journal-title":"Curr Rheumatol Rep"},{"issue":"15","key":"776_CR74","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1056\/NEJM198310133091507","volume":"309","author":"JM Wilson","year":"1983","unstructured":"Wilson JM, Young AB, Kelley WN (1983) Hypoxanthine-guanine phosphoribosyltransferase deficiency. The molecular basis of the clinical syndromes. N Engl J Med 309(15):900\u2013910","journal-title":"N Engl J Med"},{"issue":"2","key":"776_CR75","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s40620-018-0546-7","volume":"32","author":"Z Wang","year":"2019","unstructured":"Wang Z, Cui T, Ci X, Zhao F, Sun Y, Li Y, Liu R, Wu W, Yi X, Liu C (2019) The effect of polymorphism of uric acid transporters on uric acid transport. J Nephrol 32(2):177\u2013187. https:\/\/doi.org\/10.1007\/s40620-018-0546-7","journal-title":"J Nephrol"},{"issue":"1","key":"776_CR76","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s00296-017-3891-2","volume":"38","author":"C Muangchan","year":"2018","unstructured":"Muangchan C, Bhurihirun T (2018) An investigation of the independent risk factors that differentiate gout from pseudogout in patients with crystal-induced acute arthritis: a cross-sectional study. Rheumatol Int 38(1):89\u201395","journal-title":"Rheumatol Int"},{"issue":"5","key":"776_CR77","first-page":"679","volume":"56","author":"C Ben Salem","year":"2017","unstructured":"Ben Salem C, Slim R, Fathallah N, Hmouda H (2017) Drug-induced hyperuricaemia and gout. Rheumatology (Oxford) 56(5):679\u2013688","journal-title":"Rheumatology (Oxford)"},{"issue":"8","key":"776_CR78","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1136\/ard.2005.049023","volume":"65","author":"E Pascual","year":"2006","unstructured":"Pascual E, Perdiguero M (2006) Gout, diuretics and the kidney. Ann Rheum Dis 65(8):981\u2013982","journal-title":"Ann Rheum Dis"},{"key":"776_CR79","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1038\/ncomms1756","volume":"3","author":"K Ichida","year":"2012","unstructured":"Ichida K, Matsuo H, Takada T, Nakayama A, Murakami K, Shimizu T et al (2012) Decreased extra-renal urate excretion is a common cause of hyperuricemia. Nat Commun 3:764","journal-title":"Nat Commun"},{"key":"776_CR80","doi-asserted-by":"publisher","first-page":"34995","DOI":"10.1038\/srep34995","volume":"6","author":"PK Tan","year":"2016","unstructured":"Tan PK, Ostertag TM, Miner JN (2016) Mechanism of high affinity inhibition of the human urate transporter URAT1. Sci Rep 6:34995","journal-title":"Sci Rep"},{"key":"776_CR81","doi-asserted-by":"publisher","first-page":"817","DOI":"10.7326\/0003-4819-93-6-817","volume":"93","author":"FH Messerli","year":"1980","unstructured":"Messerli FH, Frohlich ED, Dreslinski GR, Suarez DH, Aristimuno GG (1980) Serum uric acid in essential hypertension: an indicator of renal vascular involvement. Ann Intern Med 93:817\u2013821","journal-title":"Ann Intern Med"},{"issue":"7","key":"776_CR82","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1111\/jcmm.13060","volume":"21","author":"M Liu","year":"2017","unstructured":"Liu M, Ning X, Li R, Yang Z, Yang X, Sun S, Qian Q (2017) Signalling pathways involved in hypoxia-induced renal fibrosis. J Cell Mol Med 21(7):1248\u20131259","journal-title":"J Cell Mol Med"},{"issue":"6","key":"776_CR83","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1093\/ndt\/gfv024","volume":"31","author":"Y Isaka","year":"2016","unstructured":"Isaka Y, Takabatake Y, Takahashi A, Saitoh T, Yoshimori T (2016) Hyperuricemia-induced inflammasome and kidney diseases. Nephrol Dial Transplant 31(6):890\u2013896","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"776_CR84","doi-asserted-by":"publisher","first-page":"F336","DOI":"10.1152\/ajprenal.00053.2010","volume":"299","author":"Z Yang","year":"2010","unstructured":"Yang Z, Xiaohua W, Lei J, Ruoyun T, Mingxia X, Weichun H, Li F, Ping W, Junwei Y (2010) Uric acid increases fibronectin synthesis through upregulation of lysyl oxidase expression in rat renal tubular epithelial cells. Am J Physiol Renal Physiol 299(2):F336\u2013346","journal-title":"Am J Physiol Renal Physiol"},{"issue":"5","key":"776_CR85","doi-asserted-by":"publisher","first-page":"F471","DOI":"10.1152\/ajprenal.00560.2012","volume":"304","author":"E-S Ryu","year":"2013","unstructured":"Ryu E-S, Kim MJ, Shin H-S, Jang YH, Choi HS, Jo I, Johnson RJ, Kang DH (2013) Uric acid-induced phenotypic transition of renal tubular cells as a novel mechanism of chronic kidney disease. Am J Physiol Renal Physiol 304(5):F471\u2013480","journal-title":"Am J Physiol Renal Physiol"},{"issue":"1","key":"776_CR86","doi-asserted-by":"publisher","first-page":"e0170393","DOI":"10.1371\/journal.pone.0170393","volume":"12","author":"C-W Tsai","year":"2017","unstructured":"Tsai C-W, Lin S-Y, Kuo C-C, Huang C-C (2017) Serum uric acid and progression of kidney disease: a longitudinal analysis and mini-review. PLoS ONE 12(1):e0170393","journal-title":"PLoS ONE"},{"issue":"12","key":"776_CR87","doi-asserted-by":"publisher","first-page":"e0145506","DOI":"10.1371\/journal.pone.0145506","volume":"10","author":"S Uchida","year":"2015","unstructured":"Uchida S, Chang WX, Ota T, Tamura Y, Shiraishi T, Kumagai T et al (2015) Targeting uric acid and the inhibition of progression to end-stage renal disease\u2014a propensity score analysis. PLoS ONE 10(12):e0145506","journal-title":"PLoS ONE"},{"issue":"3","key":"776_CR88","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1053\/j.ajkd.2017.08.017","volume":"71","author":"A Srivastava","year":"2018","unstructured":"Srivastava A, Kaze AD, McMullan CJ, Isakova T, Waikar SS (2018) Uric acid and the risks of kidney failure and death in individuals with CKD. Am J Kidney Dis 71(3):362\u2013370","journal-title":"Am J Kidney Dis"},{"key":"776_CR89","doi-asserted-by":"publisher","DOI":"10.1038\/s41581-020-0288-3","author":"S Steiger","year":"2020","unstructured":"Steiger S, Ma Q, Anders HJ (2020) The case for evidence-based medicine for the association between hyperuricaemia and CKD. Nat Rev Nephrol. https:\/\/doi.org\/10.1038\/s41581-020-0288-3(Online ahead of print)","journal-title":"Nat Rev Nephrol"},{"key":"776_CR90","doi-asserted-by":"publisher","DOI":"10.1007\/s40620-020-00702-7","author":"B Bonino","year":"2020","unstructured":"Bonino B, Leoncini G, Russo E, Pontremoli R, Viazzi F (2020) Uric acid in CKD: has the jury come to the verdict? J Nephrol. https:\/\/doi.org\/10.1007\/s40620-020-00702-7(Online ahead of print)","journal-title":"J Nephrol"},{"issue":"5","key":"776_CR91","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1007\/s40620-019-00615-0","volume":"32","author":"B Afsar","year":"2019","unstructured":"Afsar B, Sag AA, Oztosun C, Kuwabara M, Cozzolino M, Covic A, Kanbay M (2019) The role of uric acid in mineral bone disorders in chronic kidney disease. J Nephrol 32(5):709\u2013717","journal-title":"J Nephrol"},{"key":"776_CR92","doi-asserted-by":"publisher","first-page":"229","DOI":"10.7326\/0003-4819-64-2-229","volume":"64","author":"RW Rundles","year":"1966","unstructured":"Rundles RW, Metz EN, Silberman HR (1966) Allopurinol in the treatment of gout. Ann Intern Med 64:229\u2013258","journal-title":"Ann Intern Med"},{"issue":"5","key":"776_CR93","first-page":"983","volume":"20","author":"C Borghi","year":"2016","unstructured":"Borghi C, Perez-Ruiz F (2016) Urate lowering therapies in the treatment of gout: a systematic review and meta-analysis. Eur Rev Med Pharmacol Sci 20(5):983\u2013992","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"18","key":"776_CR94","first-page":"4186","volume":"21","author":"M Cutolo","year":"2017","unstructured":"Cutolo M, Cimmino MA, Perez-Ruiz F (2017) Potency on lowering serum uric acid in gout patients: a pooled analysis of registrative studies comparing febuxostat vs. allopurinol. Eur Rev Med Pharmacol Sci 21(18):4186\u20134195","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"1","key":"776_CR95","doi-asserted-by":"publisher","first-page":"21","DOI":"10.5414\/CP203466","volume":"58","author":"AY Yang","year":"2020","unstructured":"Yang AY (2020) Comparison of long-term efficacy and renal safety of febuxostat and allopurinol in patients with chronic kidney diseases. Int J Clin Pharmacol Ther 58(1):21\u201328","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"22","key":"776_CR96","first-page":"1778","volume":"40","author":"S Kojima","year":"2019","unstructured":"Kojima S, Matsui K, Hiramitsu S, Hisatome I, Waki M, Uchiyama K, Yokota N et al (2019) Febuxostat for cerebral and cardiorenovascular events prevention study eur. Heart 40(22):1778\u20131786","journal-title":"Heart"},{"issue":"13","key":"776_CR97","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1056\/NEJMoa1710895","volume":"378","author":"WB White","year":"2018","unstructured":"White WB, Saag KG, Becker MA, Borer JS, Gorelick PB, Whelton A et al (2018) Cardiovascular safety of febuxostat or allopurinol in patients with gout. N Engl J Med 378(13):1200\u20131210","journal-title":"N Engl J Med"},{"key":"776_CR98","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/j.mayocp.2019.03.001","volume":"94","author":"CY Su","year":"2019","unstructured":"Su CY, Shen LJ, Hsieh SC, Lin LY, Lin FJ (2019) Comparing Cardiovascular safety of febuxostat and allopurinol in the real world: a population-based cohort studymayo. Clin Proc 94:1147\u20131157","journal-title":"Clin Proc"},{"issue":"10","key":"776_CR99","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1038\/ajh.2008.245","volume":"21","author":"T Hamada","year":"2008","unstructured":"Hamada T, Ichida K, Hosoyamada M, Mizuta E, Yanagihara K, Sonoyama K et al (2008) Uricosuric action of losartan via the inhibition of urate transporter 1 (URAT 1) in hypertensive patients. Am J Hypertens 21(10):1157\u20131162","journal-title":"Am J Hypertens"},{"issue":"3","key":"776_CR100","doi-asserted-by":"publisher","first-page":"529","DOI":"10.7150\/ijbs.33007","volume":"16","author":"YH Lu","year":"2020","unstructured":"Lu YH, Chang YP, Li T, Han F, Mizuta E, Yanagihara K, Sonoyama K et al (2020) Empagliflozin attenuates hyperuricemia by upregulation of ABCG2 via AMPK\/AKT\/CREB signaling pathway in type 2 diabetic mice. Int J Biol Sci 16(3):529\u2013542","journal-title":"Int J Biol Sci"},{"issue":"4","key":"776_CR101","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.amjmed.2018.12.010","volume":"132","author":"MV Perez-Gomez","year":"2019","unstructured":"Perez-Gomez MV, Bartsch LA, Castillo-Rodriguez E, Fernandez-Prado R, Kanbay M, Ortiz A (2019) Potential dangers of serum urate-lowering therapy. Am J Med 132(4):457\u2013467","journal-title":"Am J Med"}],"container-title":["Journal of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-020-00776-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40620-020-00776-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-020-00776-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T15:55:12Z","timestamp":1777564512000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/joneph\/article\/34\/4\/1081\/8325845"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,16]]},"references-count":101,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["776"],"URL":"https:\/\/doi.org\/10.1007\/s40620-020-00776-3","relation":{},"ISSN":["1121-8428","1724-6059"],"issn-type":[{"value":"1121-8428","type":"print"},{"value":"1724-6059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,16]]},"assertion":[{"value":"27 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors do not have any actual or potential conflict of interest including any financial, personal or other relationships with other people or organizations within 3\u00a0years of beginning the submitted work that could inappropriately influence, or be perceived to influence, their work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"For this type of study formal consent is not required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}